A significant controversy is brewing within the Centers for Disease Control and Prevention (CDC). A key vaccine advisory panel, recently reconstituted with members appointed by Health and Human Services Secretary Robert F. Kennedy Jr., is poised to recommend delaying the hepatitis B vaccine for newborns until age four. This recommendation, expected to be voted on during the ACIP meeting on September 18-19, directly contradicts over three decades of established practice and has sparked widespread concern among public health experts and parents alike.
Former senior CDC officials, including Demetre Daskalakis, former director of the National Center for Immunization and Respiratory Diseases, express serious apprehension. Daskalakis notes the unusual lack of data analysis preceding this potential recommendation, describing the situation as "atypical." The proposed change is seen as prioritizing the opinions of newly appointed panel members over established scientific consensus and decades of successful disease prevention.
Pediatricians are vehemently opposed to the delay. Dr. Eric Ball highlights the critical importance of the newborn dose in preventing hepatitis B transmission during birth, a time when the risk is highest. Delaying vaccination leaves children vulnerable to infection, potentially leading to severe long-term health complications such as cirrhosis and liver cancer. The argument that the virus primarily spreads through sexual activity and intravenous drug use ignores the reality of transmission in everyday settings among young children, where even microscopic traces of infected blood can cause infection.
This potential policy shift has deeply impacted those living with chronic hepatitis B, like Wendy Lo, who expresses profound frustration at the prospect of future generations facing the debilitating consequences of this preventable disease. Lo's personal experience underscores the vital role of the newborn vaccine in protecting infants from infection and emphasizes the vaccine's safety and effectiveness.
The concerns extend beyond the potential health implications. If the recommendation is altered, health insurers may no longer cover the cost of the vaccine, leaving families to shoulder the financial burden. Furthermore, children receiving vaccinations through the Vaccines for Children program would lose free access to the hepatitis B shot. The abrupt change raises serious questions about transparency and the prioritization of evidence-based decision-making within the CDC.
Several experts, including Dr. William Schaffner, a professor of infectious diseases and former ACIP voting member, have expressed alarm. They point to the dramatic decrease in hepatitis B cases among children since the implementation of universal newborn vaccination and the potential for a reversal of this progress. The proposed change is not only scientifically questionable but also ethically concerning, potentially jeopardizing the health and well-being of countless children.
---
Originally published at: https://edition.cnn.com/2025/09/16/health/hepatitis-b-newborn-vaccine-cdc
